Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial Health rating, has positioned itself as an innovative player in the ...

Monoclonal antibody (mAb) therapy involves making large amounts of antibodies that recognize antigens that are usually found on the surface of cancer cells. They are then injected into the body ...

Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...

The SADA technology was developed at Memorial Sloan Kettering Cancer Center and is exclusively licensed to Y-mAbs. Presentation of significant preclinical and translational pharmacokinetics data ...

Long COVID, a debilitating condition following SARS-CoV-2 infection, continues to disable tens of millions of people globally ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

Hong Kong-listed Shanghai Henlius Biotech Inc, a subsidiary of Fosun Pharma, announced on Wednesday that its anti-PD-1 mAb, ...

The poster titled “ Preclinical and Translational Pharmacokinetics of GD2-SADA, a Self-Assembling and Disassembling (SADA) Bispecific Fusion Protein for Pretargeted Radioimmunotherapy (PRIT)” ...

Country Bowls club teamed up with the Golfers from La Torre Golf Society to have a Bowls Pro-Am event in aid of our nominated ...

Y-mAbs is highlighted as a commercial-stage biopharmaceutical company with a focus on innovative cancer treatments, showcasing its commitment to addressing unmet medical needs. The mention of ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s ...